Moderna, Inc. (NASDAQ:MRNA – Get Free Report) Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the sale, the director now directly owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Noubar Afeyan also recently made the following trade(s):
- On Tuesday, June 11th, Noubar Afeyan sold 202,832 shares of Moderna stock. The shares were sold at an average price of $148.34, for a total value of $30,088,098.88.
- On Wednesday, June 5th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $151.25, for a total value of $2,268,750.00.
- On Wednesday, May 29th, Noubar Afeyan sold 20,000 shares of Moderna stock. The stock was sold at an average price of $145.08, for a total value of $2,901,600.00.
- On Wednesday, May 22nd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $157.57, for a total transaction of $2,363,550.00.
- On Wednesday, May 15th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $127.32, for a total transaction of $1,909,800.00.
- On Wednesday, May 8th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.68, for a total value of $1,825,200.00.
- On Wednesday, May 1st, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00.
- On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00.
- On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00.
- On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00.
Moderna Stock Down 2.0 %
MRNA stock opened at $118.75 on Friday. The company has a 50 day moving average price of $134.13 and a two-hundred day moving average price of $111.96. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The stock has a market capitalization of $45.51 billion, a P/E ratio of -7.58 and a beta of 1.54. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47.
Wall Street Analyst Weigh In
A number of research firms recently commented on MRNA. William Blair reissued a “market perform” rating on shares of Moderna in a report on Thursday. Canaccord Genuity Group upped their price target on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Royal Bank of Canada lifted their price objective on Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, June 3rd. UBS Group upped their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $214.00 price target on shares of Moderna in a research note on Thursday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $134.02.
Read Our Latest Research Report on Moderna
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. LPL Financial LLC raised its position in shares of Moderna by 7.2% in the 3rd quarter. LPL Financial LLC now owns 115,782 shares of the company’s stock worth $11,959,000 after buying an additional 7,811 shares during the period. Mariner LLC lifted its stake in shares of Moderna by 5.2% in the 3rd quarter. Mariner LLC now owns 20,242 shares of the company’s stock valued at $2,091,000 after purchasing an additional 996 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of Moderna by 19.0% during the 3rd quarter. Stifel Financial Corp now owns 75,871 shares of the company’s stock worth $7,837,000 after purchasing an additional 12,099 shares during the period. Natixis Advisors L.P. increased its position in Moderna by 19.9% during the 3rd quarter. Natixis Advisors L.P. now owns 19,924 shares of the company’s stock worth $2,058,000 after purchasing an additional 3,310 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC increased its position in Moderna by 34.0% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 7,664 shares of the company’s stock worth $792,000 after purchasing an additional 1,945 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More
- Five stocks we like better than Moderna
- The Significance of Brokerage Rankings in Stock Selection
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 6/24 – 6/28
- Roth IRA Calculator: Calculate Your Potential Returns
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.